This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Firsov, A. A.
Right arrow Articles by Zinner, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Firsov, A. A.
Right arrow Articles by Zinner, S. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2003, p. 1604-1613, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1604-1613.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus

Alexander A. Firsov,1* Sergey N. Vostrov,1 Irene Y. Lubenko,1 Karl Drlica,2 Yury A. Portnoy,1 and Stephen H. Zinner3

Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia,1 Public Health Research Institute, New York, New York,2 Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts3

Received 24 June 2002/ Returned for modification 9 November 2002/ Accepted 30 January 2003

To study the hypothesis of the mutant selection window (MSW) in a pharmacodynamic context, the susceptibility of a clinical isolate of methicillin-resistant Staphylococcus aureus exposed to moxifloxacin (MOX), gatifloxacin (GAT), levofloxacin (LEV), and ciprofloxacin (CIP) was tested daily by using an in vitro dynamic model that simulates human pharmacokinetics. A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (Cmax) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or "inside" the MSW), or exceeded the MPC. The respective ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC24) to the MIC varied from 13 to 244 h, and the starting inoculum was 108 CFU/ml (6 x 109 CFU per 60-ml central compartment). With all four quinolones, the greatest increases in MIC were observed at those AUC24/MIC values (from 24 to 62 h) that corresponded to quinolone concentrations within the MSW over most of the dosing interval (>20%). Less-pronounced increases in MIC were associated with the smallest simulated AUC24/MIC values (15 to 16 h) of GAT and CIP, whose Cmax exceeded the MICs. No such increases were observed with the smallest AUC24/MIC values (13 to 17 h) of MOX and LEV, whose Cmax were close to the MICs. Also, less pronounced but significant increases in MIC occurred at AUC24/MIC values (107 to 123 h) that correspond to quinolone concentrations partly overlapping the MIC-to-MPC range. With all four drugs, no change in MIC was seen at the highest AUC24/MIC values (201 to 244 h), where quinolone concentrations exceeded the MPC over most of the dosing interval. These "protective" AUC24/MIC ratios correspond to 66% of the usual clinical dose of MOX (400 mg), 190% of a 400-mg dose of GAT, 220% of a 500-mg dose of LEV, and 420% of two 500-mg doses of CIP. Thus, MOX may protect against resistance development at subtherapeutic doses, whereas GAT, LEV, and CIP provide similar effects only at doses that exceed their usual clinical doses. These data support the concept that resistant mutants are selectively enriched when antibiotic concentrations fall inside the MSW and suggest that in vitro dynamic models can be used to predict the relative abilities of quinolones to prevent mutant selection.

* Corresponding author. Mailing address: Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya St., Moscow, 119021 Russia. Phone: 7 (095) 245-0154. Fax: 7 (095) 245-0295. E-mail: firsov{at}dol.ru.

Antimicrobial Agents and Chemotherapy, May 2003, p. 1604-1613, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1604-1613.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kesteman, A.-S., Ferran, A. A., Perrin-Guyomard, A., Laurentie, M., Sanders, P., Toutain, P.-L., Bousquet-Melou, A. (2009). Influence of Inoculum Size and Marbofloxacin Plasma Exposure on the Amplification of Resistant Subpopulations of Klebsiella pneumoniae in a Rat Lung Infection Model. Antimicrob. Agents Chemother. 53: 4740-4748 [Abstract] [Full Text]  
  • Smirnova, M. V., Vostrov, S. N., Strukova, E. V., Dovzhenko, S. A., Kobrin, M. B., Portnoy, Y. A., Zinner, S. H., Firsov, A. A. (2009). The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models. J Antimicrob Chemother 64: 815-820 [Abstract] [Full Text]  
  • Allen, G. P., Hankins, C. D. (2009). Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae. J Antimicrob Chemother 64: 359-363 [Abstract] [Full Text]  
  • Ferran, A. A., Kesteman, A.-S., Toutain, P.-L., Bousquet-Melou, A. (2009). Pharmacokinetic/Pharmacodynamic Analysis of the Influence of Inoculum Size on the Selection of Resistance in Escherichia coli by a Quinolone in a Mouse Thigh Bacterial Infection Model. Antimicrob. Agents Chemother. 53: 3384-3390 [Abstract] [Full Text]  
  • Murillo, O., Pachon, M. E., Euba, G., Verdaguer, R., Tubau, F., Cabellos, C., Cabo, J., Gudiol, F., Ariza, J. (2008). Antagonistic Effect of Rifampin on the Efficacy of High-Dose Levofloxacin in Staphylococcal Experimental Foreign-Body Infection. Antimicrob. Agents Chemother. 52: 3681-3686 [Abstract] [Full Text]  
  • Firsov, A. A., Lubenko, I. Y., Smirnova, M. V., Strukova, E. N., Zinner, S. H. (2008). Enrichment of Fluoroquinolone-Resistant Staphylococcus aureus: Oscillating Ciprofloxacin Concentrations Simulated at the Upper and Lower Portions of the Mutant Selection Window. Antimicrob. Agents Chemother. 52: 1924-1928 [Abstract] [Full Text]  
  • Zinner, S. H., Gilbert, D., Lubenko, I. Yu., Greer, K., Firsov, A. A. (2008). Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline. J Antimicrob Chemother 61: 629-635 [Abstract] [Full Text]  
  • Quinn, B., Hussain, S., Malik, M., Drlica, K., Zhao, X. (2007). Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus. J Antimicrob Chemother 60: 1380-1383 [Abstract] [Full Text]  
  • Oonishi, Y., Mitsuyama, J., Yamaguchi, K. (2007). Effect of GrlA mutation on the development of quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model. J Antimicrob Chemother 60: 1030-1037 [Abstract] [Full Text]  
  • Homma, T., Hori, T., Sugimori, G., Yamano, Y. (2007). Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3810-3815 [Abstract] [Full Text]  
  • Ferran, A., Dupouy, V., Toutain, P.-L., Bousquet-Melou, A. (2007). Influence of Inoculum Size on the Selection of Resistant Mutants of Escherichia coli in Relation to Mutant Prevention Concentrations of Marbofloxacin. Antimicrob. Agents Chemother. 51: 4163-4166 [Abstract] [Full Text]  
  • Olofsson, S. K., Marcusson, L. L., Stromback, A., Hughes, D., Cars, O. (2007). Dose-related selection of fluoroquinolone-resistant Escherichia coli. J Antimicrob Chemother 60: 795-801 [Abstract] [Full Text]  
  • Stearne, L. E. T., Goessens, W. H. F., Mouton, J. W., Gyssens, I. C. (2007). Effect of Dosing and Dosing Frequency on the Efficacy of Ceftizoxime and the Emergence of Ceftizoxime Resistance during the Early Development of Murine Abscesses Caused by Bacteroides fragilis and Enterobacter cloacae Mixed Infection. Antimicrob. Agents Chemother. 51: 3605-3611 [Abstract] [Full Text]  
  • Grossi, O., Caillon, J., Arvieux, C., Jacqueline, C., Bugnon, D., Potel, G., Hamel, A. (2007). In Vivo Efficacy of Moxifloxacin Compared with Cloxacillin and Vancomycin in a Staphylococcus aureus Rabbit Arthritis Experimental Model. Antimicrob. Agents Chemother. 51: 3401-3403 [Abstract] [Full Text]  
  • Turnidge, J., Paterson, D. L. (2007). Setting and Revising Antibacterial Susceptibility Breakpoints. Clin. Microbiol. Rev. 20: 391-408 [Abstract] [Full Text]  
  • Gumbo, T., Louie, A., Liu, W., Brown, D., Ambrose, P. G., Bhavnani, S. M., Drusano, G. L. (2007). Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations. Antimicrob. Agents Chemother. 51: 2329-2336 [Abstract] [Full Text]  
  • Firsov, A. A., Smirnova, M. V., Lubenko, I. Yu., Vostrov, S. N., Portnoy, Y. A., Zinner, S. H. (2006). Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 58: 1185-1192 [Abstract] [Full Text]  
  • French, G. L. (2006). Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. J Antimicrob Chemother 58: 1107-1117 [Abstract] [Full Text]  
  • Andes, D., Forrest, A., Lepak, A., Nett, J., Marchillo, K., Lincoln, L. (2006). Impact of Antimicrobial Dosing Regimen on Evolution of Drug Resistance In Vivo: Fluconazole and Candida albicans.. Antimicrob. Agents Chemother. 50: 2374-2383 [Abstract] [Full Text]  
  • Andes, D., Lepak, A., Nett, J., Lincoln, L., Marchillo, K. (2006). In Vivo Fluconazole Pharmacodynamics and Resistance Development in a Previously Susceptible Candida albicans Population Examined by Microbiologic and Transcriptional Profiling.. Antimicrob. Agents Chemother. 50: 2384-2394 [Abstract] [Full Text]  
  • Zhanel, G. G., Mayer, M., Laing, N., Adam, H. J. (2006). Mutant Prevention Concentrations of Levofloxacin Alone and in Combination with Azithromycin, Ceftazidime, Colistin (Polymyxin E), Meropenem, Piperacillin-Tazobactam, and Tobramycin against Pseudomonas aeruginosa.. Antimicrob. Agents Chemother. 50: 2228-2230 [Abstract] [Full Text]  
  • Olofsson, S. K., Marcusson, L. L., Komp Lindgren, P., Hughes, D., Cars, O. (2006). Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 57: 1116-1121 [Abstract] [Full Text]  
  • Olofsson, S. K., Geli, P., Andersson, D. I., Cars, O. (2005). Pharmacodynamic Model To Describe the Concentration-Dependent Selection of Cefotaxime-Resistant Escherichia coli. Antimicrob. Agents Chemother. 49: 5081-5091 [Abstract] [Full Text]  
  • Campion, J. J., Chung, P., McNamara, P. J., Titlow, W. B., Evans, M. E. (2005). Pharmacodynamic Modeling of the Evolution of Levofloxacin Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 2189-2199 [Abstract] [Full Text]  
  • Marcusson, L. L., Olofsson, S. K., Lindgren, P. K., Cars, O., Hughes, D. (2005). Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother 55: 938-943 [Abstract] [Full Text]  
  • Hermsen, E. D., Hovde, L. B., Konstantinides, G. N., Rotschafer, J. C. (2005). Mutant Prevention Concentrations of ABT-492, Levofloxacin, Moxifloxacin, and Gatifloxacin against Three Common Respiratory Pathogens. Antimicrob. Agents Chemother. 49: 1633-1635 [Abstract] [Full Text]  
  • Campion, J. J., McNamara, P. J., Evans, M. E. (2004). Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments. Antimicrob. Agents Chemother. 48: 4733-4744 [Abstract] [Full Text]  
  • Liu, Y. Q., Zhang, Y. Z., Gao, P. J. (2004). Novel Concentration-Killing Curve Method for Estimation of Bactericidal Potency of Antibiotics in an In Vitro Dynamic Model. Antimicrob. Agents Chemother. 48: 3884-3891 [Abstract] [Full Text]  
  • Epstein, B. J, Gums, J. G, Drlica, K. (2004). The Changing Face of Antibiotic Prescribing: The Mutant Selection Window. The Annals of Pharmacotherapy 38: 1675-1682 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Piroth, L., Bergoin, E., Lequeu, C., Portier, H., Chavanet, P. (2004). In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother 54: 640-647 [Abstract] [Full Text]  
  • Eick, S., Schmitt, A., Sachse, S., Schmidt, K.-H., Pfister, W. (2004). In vitro antibacterial activity of fluoroquinolones against Porphyromonas gingivalis strains. J Antimicrob Chemother 54: 553-556 [Abstract] [Full Text]  
  • Firsov, A. A., Vostrov, S. N., Lubenko, I. Yu., Arzamastsev, A. P., Portnoy, Y. A., Zinner, S. H. (2004). ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother 54: 178-186 [Abstract] [Full Text]  
  • Rodriguez, J. C., Cebrian, L., Lopez, M., Ruiz, M., Jimenez, I., Royo, G. (2004). Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 53: 441-444 [Abstract] [Full Text]  
  • Linde, H.-J., Lehn, N. (2004). Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J Antimicrob Chemother 53: 252-257 [Abstract] [Full Text]  
  • Zinner, S. H., Lubenko, I. Yu., Gilbert, D., Simmons, K., Zhao, X., Drlica, K., Firsov, A. A. (2003). Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 52: 616-622 [Abstract] [Full Text]  
  • Drlica, K. (2003). The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17 [Abstract] [Full Text]  
  • Lu, T., Zhao, X., Li, X., Hansen, G., Blondeau, J., Drlica, K. (2003). Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother 52: 61-64 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»